As demand for weight-loss medications continues to soar, federal regulators are preparing to make important decisions that could affect the availability and safety of compounded GLP-1 drugs and peptide products. Shabbir Imber Safdar, Executive Director of the Partnership for Safe Medicines, joined Jeff Hamlin to discuss that the next moves mean for consumers.